| Authors | Eapen, Mathew Suji Hansbro, Philip M Larsson‑Callerfelt, Anna-Karin Jolly, Mohit K Myers, Stephen Sharma, Pawan Jones, Bernadette Rahman, Md Atiqur Markos, James Chia, Collin |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | Drugs |
| PubMed ID | 30392114 |
| Year of Publication | 2018 |
| URL | https://www.ncbi.nlm.nih.gov/pubmed/30392114 |
| DOI | https://doi.org/10.1007/s40265-018-1001-8 |
| Abstract | Chronic obstructive pulmonary disease (COPD) and lung cancer are major lung diseases affecting millions worldwide. Both diseases have links to cigarette smoking and exert a considerable societal burden. People suffering from COPD are at higher risk of developing lung cancer than those without, and are more susceptible to poor outcomes after diagnosis and treatment. Lung cancer and COPD are closely associated, possibly sharing common traits such as an underlying genetic predisposition, epithelial and endothelial cell plasticity, dysfunctional inflammatory mechanisms including the deposition of excessive extracellular matrix, angiogenesis, susceptibility to DNA damage and cellular mutagenesis. In fact, COPD could be the driving factor for lung cancer, providing a conducive environment that propagates its evolution. In the early stages of smoking, body defences provide a combative immune/oxidative response and DNA repair mechanisms are likely to subdue these changes to a certain extent; however, in patients with COPD with lung cancer the consequences could be devastating, potentially contributing to slower postoperative recovery after lung resection and increased resistance to radiotherapy and chemotherapy. Vital to the development of new-targeted therapies is an in-depth understanding of various molecular mechanisms that are associated with both pathologies. In this comprehensive review, we provide a detailed overview of possible underlying factors that link COPD and lung cancer, and current therapeutic advances from both human and preclinical animal models that can effectively mitigate this unholy relationship |
http://www.ibas.org.au/what-we-do/publications/3873005
Interstitial lung disease (ILD) is a chronic lung condition that causes stiff lungs and restricts sufferers from taking a deep breath. Exercise in a gym, such as walking or riding a bike, can help make...
Each year in Australia 260 people sustain a SCI, with over half losing full function in their arms and legs (quadriplegia). In addition to the primary disability, there is a very high rate of Obstructive...
DO YOU HAVE SPINAL CORD INJURY? TIRED? GET TREATED!
Melbourne researchers have found that 80 percent of people with quadriplegic spinal injuries have sleep apnoea. It's having a big effect on their lives but they don't know they have it, and they don't know it can be treated.
WORLD 1ST HEAVY VEHICLE DRIVER FATIGUE STUDY RELEASED
The National Transport Commission (NTC) and the Cooperative Research Centre for Alertness, Safety and Productivity (Alertness CRC) have released the results of what is hailed as a world-first study into heavy vehicle driver fatigue.
AAMRI ELECTION STATEMENT RELEASED ON 25TH MARCH 2019
AAMRI released its election statement calling on politicians to commit to three main priorities: ensuring the MRFF reaches $20 billion by 2020-21, provide continued strong support for the NHMRC, and develop sustainable and rewarding career pathways.
PORTRAIT UNVEILED AT CANBERRA'S PARLIAMENT HOUSE
IBAS Director Anna Burke had barely got into the swing of her speech at the unveiling of her portrait at Canberra's Parliament House when the ringing of bells caused half her audience to hurry away.
© 2020 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
